MedPath

Analysis of Blood Culture and antibacterial Drugs in Classical empiric therapy vs. D-index-guided early therapy using micafungin for persistent febrile neutropenia.(ABCD-CEDMIC trial)

Not Applicable
Conditions
Hematological malignancies(acute leukemia, myelodysplastic syndrome, lymphoma, myeloma, and so on)
Registration Number
JPRN-UMIN000040390
Lead Sponsor
Japan Febrile Neutropenia Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
423
Inclusion Criteria

Not provided

Exclusion Criteria

1)Previous history of invasive fungal infection 2)Receiving antifungal agents other than prophylactic administration 3)Suspected active infection 4)Planned to receive antifungal prophylaxis with polyenes or candins 5)Allergic reaction to candins 6)Pregnant or possibly pregnant 7)HIV positive 8)Not suitable for thie trial judged by attending physicians

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To detect the pathogens and confirm the risk factor
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath